scholarly journals Salmonella Paratyphi B bacteremia in Systemic Lupus Erythematosus with an unusual presentation- a case report

2014 ◽  
Vol 2 (03) ◽  
pp. 73-75
Author(s):  
Madhuri Kulkarni ◽  
K. G. Rajeshwari ◽  
A. Tejashree ◽  
R. Subramanian
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Bacterial Infections ◽  
Rare Case ◽  
Immunosuppressive Agents ◽  
Autoimmune Disorder ◽  
Systemic Lupus ◽  
Juvenile Onset ◽  
Increased Risk ◽  
Paratyphi B

Background- Systemic Lupus Erythematosus (SLE) is an inflammatory and multisystem autoimmune disorder. Patients of SLE are at increased risk of infections owing to underlying immunological derangements and to the use of therapeutic regimens like immunosuppressive agents. Among the bacterial infections presenting as bacteremia in these patients, non typhoidal and typhoidal salmonellosis are commonly encountered. We report a rare case of Salmonella Paratyphi B bacteremia in a patient with juvenile onset SLE on treatment with corticosteroids.

scholarly journals Systemic lupus erythematosus and infections

Reumatismo ◽  
2020 ◽  
Vol 72 (3) ◽  
pp. 154-169
Author(s):  
B.K. Singh ◽  
S. Singh
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Opportunistic Infections ◽  
Immunosuppressive Agents ◽  
Immune Dysregulation ◽  
Systemic Lupus ◽  
Irreversible Damage ◽  
Increased Risk ◽  
Increased Susceptibility

Systemic lupus erythematosus (SLE) is an inflammatory and multi-systemic autoimmune disorder, characterized by an uncontrolled auto-reactivity of B and T lymphocytes, leading to the production of autoantibodies against self-directed antigens and tissue damage. The life expectancy in patients with SLE has improved tremendously in the last two decades, but the mortality rates still remain three times greater compared to those of the general population. Despite increased awareness and improved management, infections remain a major source of morbidity, mortality, hospitalization, and death in patients with SLE. The infections in SLE patients widely range from opportunistic to common bacterial and viral infections with typical or atypical presentations. Moreover, SLE patients exhibit an increased susceptibility to hospital-acquired infections. Factors associated with increased risk of infections include high disease activity, specific immune dysregulation, drug-induced immune deficiency, and organ failure with irreversible damage. Furthermore, immunosuppressive agents may make patients more susceptible to opportunistic infections. A big challenge faced by physicians in these patients is to distinguish between infections and flares of SLE, as infections may mimic them, leading to predicament in diagnosis and appropriate management. Immunosuppression used to treat severe flares of lupus can have catastrophic complications in patients with active infections. There is an urgent need for biomarkers to make an accurate differential diagnosis in this situation. In spite of increased understanding of SLE, many questions remain unanswered. Further research is needed to determine specific immune dysregulation underlying the increased susceptibility to specific infections, predictors of infection in SLE such as genetic markers, and biomarkers that discriminate between disease activity and active infections. Also, measures must be evaluated appropriately to prevent infections, and their complications in SLE.

scholarly journals Lupus Eritematoso Sistêmico: Novos Paradigmas e Manejo no Atendimento Emergencial – Revisão de Literatura

2020 ◽  
Vol 4 (1) ◽  
pp. 57-62
Author(s):  
Rita Mira ◽  
Luan Guanais Soriano ◽  
Catharine Bittencourt Cunha ◽  
Ramon Campos Nascimento
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Juvenile Onset ◽  
Treatment Regimens ◽  
Adaptive Immune ◽  
Autoreactive Antibodies ◽  
Increased Risk ◽  
Adaptive Immune Systems ◽  
Onset Systemic Lupus Erythematosus

O lupus eritematoso sistêmico é uma doença autoimune heterogênea, resultante de desregulação complexa do sistema imunológico inato e adaptativo, afetando potencialmente qualquer órgão e / ou tecido. O lupus eritematoso sistêmico é uma doença imunemediada cuja patogênese originária resulta em exposição a autoantígeno, dando origem a numerosos anticorpos auto-reativos de especificidades antigênicas variadas que, juntamente com uma infinidade de citocinas, são consideradas efetoras da atividade da doença. Os regimes de tratamento existentes estão associados a vários efeitos colaterais debilitantes, com pacientes mais jovens em risco aumentado devido à duração do tratamento. Este trabalho teve como objetivo revisar e resumir sistematicamente a literatura disponível sobre a temática do lupus eritematoso sistêmico na população pediatrica através da revisão sistemática por meio de artigos disponibilizados atraves do PubMed e contextualizar a temática por meio de um relato de caso clínico.   Systemic lupus erythematosus is a heterogeneous autoimmune disease, resulting from complex dysregulation of the innate and adaptive immune systems, potentially affecting any organ and/or tissue.Systemic lupus erythematosus is an immunemediated disease whose originating pathogenesis results in autoantigen exposure giving rise to numerous autoreactive antibodies of varying antigenic specificities that along with a myriad of cytokines are thought to be effectors of disease activity.Existing treatment regimens are associated with numerous debilitating side effects, with younger patients at increased risk due to the duration of their disease. This study aimed reviewing and summarizing the available literature of juvenile-onset systemic lupus erythematosus by using articles on PubMed and a case report was related to elucidate the disease.

scholarly journals COLD ANTIBODY-MEDIATED AUTOIMMUNE HEMOLYTIC ANEMIA IN A PATIENT WITH OVERLAP SYNDROME OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH SJOGREN’S SYNDROME

2019 ◽  
pp. 3-4
Author(s):  
INDIRA BAIRY ◽  
ANUPAM BERWAL ◽  
CHARANTHEJREDDY V ◽  
MUKHYAPRANA PRABHU
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Female Patient ◽  
Hemolytic Anemia ◽  
Lupus Erythematosus ◽  
Autoimmune Hemolytic Anemia ◽  
Blood Cells ◽  
Rare Case ◽  
Autoimmune Disorder ◽  
Overlap Syndrome ◽  
Systemic Lupus

Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder commonly seen in females characterized by multisystem inflammation with the production of an array of antibodies. Hematological disturbances are common in SLE specifically autoimmune hemolytic anemia (AIHA) which results from the development of autoantibodies directed against antigens on the surface of patient’s own red blood cells. Here, we present a rare case of a 50-year-old female patient presenting with cold antibody-mediated AIHA.

scholarly journals Successful outcome of pregnancy in a case of systemic lupus erythematosus : a case report

2019 ◽  
Vol 6 (4) ◽  
pp. 1340
Author(s):  
Gurinder Mohan ◽  
Avleen Kaur ◽  
Umang Khullar
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Immunosuppressive Agents ◽  
Reproductive Age ◽  
Intrauterine Fetal Death ◽  
Successful Outcome ◽  
Antiphospholipid Antibody ◽  
Systemic Lupus ◽  
Emergency Cesarean ◽  
Increased Risk

Systemic lupus erythematosus (SLE) is a multisystem, auto immune connective tissue disease that commonly affects women of reproductive age and may coexist with pregnancy. The autoantibodies and immune complexes lead to damage of various organs and tissues. Pregnant woman with SLE have increased risk of spontaneous abortion, preterm delivery, intrauterine growth retardation, preeclampsia, neonatal lupus, stillbirth and intrauterine fetal death. The therapeutic intervention with anticoagulants, steroids, immunosuppressive agents pose a high risk to both mother and fetus. A multidisciplinary approach and close medical, obstetrical and neonatal monitoring leads to optimal outcome. Authors describe a successful management of an antenatal patient with positive antinuclear antibody, anti-ds DNA antibody and antiphospholipid antibody with bad obstetric history. She underwent an emergency cesarean section and delivered a healthy female child.

scholarly journals Subclinical atherosclerosis in young Thai adults with juvenile-onset systemic lupus erythematosus

2016 ◽  
Vol 10 (2) ◽  
Author(s):  
Nalinee Pattrakornkul ◽  
Patamakom Pruangprasert ◽  
Prakul Chanthong ◽  
Ratana Chawanasuntorapoj ◽  
Anirut Pattaragarn
Keyword(s):  
Risk Factors ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Subclinical Atherosclerosis ◽  
Disease Stage ◽  
Healthy Population ◽  
Systemic Lupus ◽  
Juvenile Onset ◽  
Persistent Proteinuria ◽  
Increased Risk

AbstractBackgroundCardiovascular disease (CVD) is a leading cause of morbidity and mortality in adult patients with systemic lupus erythematosus (SLE). Increased risk of CVD and atherosclerosis has been demonstrated in children with SLE. However, evidence of atherosclerosis in adults with juvenile-onset SLE is limited and their additional CVD risk factors unclear.ObjectivesTo investigate the presence of subclinical atherosclerosis in young Thai adults with juvenile-onset SLE, and evaluate atherosclerotic risk factors.MethodsWe recruited a cohort of patients aged 18-40 years who had been diagnosed SLE before the age of 18 years for this observational study. Patients with chronic kidney disease stage IV or V, alcoholism, chronic liver disease, or life threatening illness were excluded. Common carotid intima-media thickness (CCIMT) was measured. Clinical and laboratory parameters, treatment, and SLE-related factors, which could be risk factors for atherosclerosis and classic risk factors were obtained.ResultsWe enrolled 29 patients (24 female). Their mean age was 25.1 years and mean disease duration 11.3 years. The age of participants, persistent proteinuria and use of cyclosporin correlated with increased CCIMT by multivariable analysis (P = 0.02, 0.02, and 0.03, respectively). These patients had significantly abnormal CCIMT when compared with a healthy population (mean 690 (SD 150) μm versus mean 447 (SD 76) μm, respectively; P < 0.001).ConclusionsSubclinical atherosclerosis, identified by abnormal CCIMT, appears in young adults with juvenile-onset SLE. The CCIMT abnormality progresses with increasing age, and persistent proteinuria and use of cyclosporin appears to increase the risk for atherosclerosis.

scholarly journals Vaccination of Patients with Systemic Lupus Erythematosus

2020 ◽  
Vol 95 (3) ◽  
pp. 170-175
Author(s):  
Chang-Nam Son ◽  
Sang-Hyon Kim
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Hepatitis A ◽  
Immunosuppressive Agents ◽  
Risk Of Infection ◽  
Systemic Lupus ◽  
Increased Risk ◽  
Inflammatory Autoimmune Disease ◽  
Chronic Inflammatory Autoimmune Disease ◽  
Lupus Disease Activity

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that affects various organs. SLE patients have an increased risk of infection compared to the general population. Immunosuppressive agents commonly used in SLE increase the risk of infection. Vaccination is a good way to reduce the risk of infection. However, some SLE patients are concerned that vaccination may worsen lupus disease activity or cause side effects. The latest SLE patient vaccination data were reviewed in this study, which focused on the safety, immunogenicity, and efficacy of influenza, pneumococcal, tetanus, hepatitis A, herpes zoster, and human papillomavirus vaccines. Korean immunization recommendations were also compared to those of other countries.

Bone impairment assessed by HR-pQCT in juvenile-onset systemic lupus erythematosus

2015 ◽  
Vol 27 (5) ◽  
pp. 1839-1848 ◽  
Author(s):  
J. A. Paupitz ◽  
G. L. Lima ◽  
J. C. Alvarenga ◽  
R. M. Oliveira ◽  
E. Bonfa ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Juvenile Onset ◽  
Onset Systemic Lupus Erythematosus

A Rare Case of Hb H Disease and Systemic Lupus Erythematosus

Hemoglobin ◽  
2021 ◽  
Vol 45 (1) ◽  
pp. 66-68
Author(s):  
Qi-Yin Lin ◽  
Di-Yu Chen ◽  
Shu Kong ◽  
Wei-Qiang Liu ◽  
Xiao-Fang Sun ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Rare Case ◽  
Systemic Lupus ◽  
Hb H Disease

scholarly journals Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Sarfaraz A. Hasni ◽  
Sarthak Gupta ◽  
Michael Davis ◽  
Elaine Poncio ◽  
Yenealem Temesgen-Oyelakin ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Controlled Clinical Trial ◽  
Type I ◽  
Systemic Lupus ◽  
Double Blind ◽  
Premature Cardiovascular Disease ◽  
Increased Risk

AbstractIncreased risk of premature cardiovascular disease (CVD) is well recognized in systemic lupus erythematosus (SLE). Aberrant type I-Interferon (IFN)-neutrophil interactions contribute to this enhanced CVD risk. In lupus animal models, the Janus kinase (JAK) inhibitor tofacitinib improves clinical features, immune dysregulation and vascular dysfunction. We conducted a randomized, double-blind, placebo-controlled clinical trial of tofacitinib in SLE subjects (ClinicalTrials.gov NCT02535689). In this study, 30 subjects are randomized to tofacitinib (5 mg twice daily) or placebo in 2:1 block. The primary outcome of this study is safety and tolerability of tofacitinib. The secondary outcomes include clinical response and mechanistic studies. The tofacitinib is found to be safe in SLE meeting study’s primary endpoint. We also show that tofacitinib improves cardiometabolic and immunologic parameters associated with the premature atherosclerosis in SLE. Tofacitinib improves high-density lipoprotein cholesterol levels (p = 0.0006, CI 95%: 4.12, 13.32) and particle number (p = 0.0008, CI 95%: 1.58, 5.33); lecithin: cholesterol acyltransferase concentration (p = 0.024, CI 95%: 1.1, −26.5), cholesterol efflux capacity (p = 0.08, CI 95%: −0.01, 0.24), improvements in arterial stiffness and endothelium-dependent vasorelaxation and decrease in type I IFN gene signature, low-density granulocytes and circulating NETs. Some of these improvements are more robust in subjects with STAT4 risk allele.

Sign in / Sign up

Export Citation Format

Share Document